Synergistic effect of compounds directed to triosephosphate isomerase, a combination to develop drug against trichomoniasis

Abstract

The development of new drugs is continuous in the world; currently, saving resources (both economic ones and time) and preventing secondary effects have become a necessity for drug developers. Trichomoniasis is the most common nonviral sexually transmitted infection affecting more than 270 million people around the world. In our research group, we focussed on developing a selective and more effective drug against Trichomonas vaginalis, and we previously reported on a compound, called A4, which had a trichomonacidal effect. Later, we determined another compound, called D4, which also had a trichomonacidal effect together with favorable toxicity results. Both A4 and D4 are directed at the enzyme triosephosphate isomerase. Thus, we made combinations between the two compounds, in which we determined a synergistic effect against T. vaginalis, determining the IC 50 and the toxicity of the best relationship to obtain the trichomonacidal effect. With these results, we can propose a combination of compounds that represents a promising alternative for the development of a new therapeutic strategy against trichomoniasis.

Compounds Interacting with Cholecystokinin as Potential Drugs Against Excessive Weight Gain and Obesity

“…For this assay we used fibroblast cells as described previously. [62,63] The MTT viability assay was performed as described previously. [64,65] Cells in 96-well microplates were treated for 48 hours at concentrations between 10 and 500 μM of K2 and K5 compounds.…”